California-based Tempest Therapeutics is laying off 21 of its 26 full-time employees. The cuts come while the biotech is ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in ...

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.

Scotiabank analyst George Farmer downgraded Tempest Therapeutics (TPST) to Sector Perform from Outperform with a reverse stock-split adjusted ...

"We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include finding a strategic partner with the resources to develop what we believe are ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, to TPST-1495, the ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

including the anticipated Phase 3 study for amezalpat; anticipated therapeutic benefit and regulatory development of the Company’s product candidates the Company’s ability to advance into a ...